Damora Therapeutics, Inc. 8-K

What Happened

• Damora Therapeutics, Inc. (DMRA) announced the appointment of Jennifer Jarrett as President and Chief Executive Officer, effective March 30, 2026. She will succeed Sherwin Sattarzadeh as principal executive officer; Mr. Sattarzadeh will remain as Chief Operating Officer.
• Three directors—Amit Munshi, Carl Goldfischer and Jayson Dallas—resigned effective March 23, 2026; their equity awards were fully accelerated. Michael Landsittel and Cameron Turtle were appointed as directors effective March 23, 2026, and Peter Harwin was named Board chair. The Board size was reduced from seven to six members.
• The company furnished a press release on March 23, 2026 announcing these leadership and director changes.

Key Details

• CEO pay and incentives: Ms. Jarrett’s base salary is $695,000 with a target annual bonus of 55% of base salary.
• CEO equity and severance: Initial equity inducements include 500,000 RSUs vesting over four years and options for 1,500,000 shares (25% vest after one year, then monthly over four years). If terminated without cause or for good reason, severance ranges from 12 months’ base pay (or 18 months around a change in control) plus health continuation, prorated/owed bonuses, and accelerated vesting provisions as described in her offer letter.
• New director compensation: Michael Landsittel and Dr. Cameron Turtle receive cash retainers and an initial option grant under the 2026 Equity Plan (up to 40,000 shares or a value-based share number), vesting over three years. Mr. Landsittel was named audit committee chair; Dr. Turtle joined the audit committee.
• General Counsel update: Garrett Winslow signed an offer letter (dated March 20, 2026) with base salary $440,000, target bonus 40%, and options to purchase 250,000 shares vesting over four years; severance and change-in-control terms are included.

Why It Matters

• Leadership and governance: A new CEO and multiple board appointments change the company’s top leadership and oversight — important for how management sets strategy, operations and investor communications going forward.
• Compensation and dilution: Large equity grants (RSUs and option packages) to the incoming CEO, new directors and general counsel are material to shareholders because they can increase share-based compensation expense and potential share dilution when exercised or vested.
• Governance focus: Appointment of a new audit committee chair and committee memberships may affect financial oversight and reporting priorities.
• Contract terms: Severance and change-in-control protections for senior executives are documented and could have material cash and equity consequences under certain termination or transaction scenarios.

Exhibits referenced in the filing include the CEO and GC offer letters and the company press release.